KOP Therapeutics
INVESTOR RELATIONS

A Differentiated Oncology
Investment Opportunity

KOP Therapeutics is seeking strategic partners and investors to advance its knockdown oncology platform toward IND-enabling development and clinical proof-of-concept. Biostatistician-confirmed preclinical results. Modular pipeline. Capital-efficient architecture.

95%

Peak Knockdown

Next-gen sequences, preclinical

Confirmed

Tumor Growth Inhibition

Charles River · p=0.049

4

Pipeline Programs

Prostate · Breast · Brain · Ovarian

0

Observed Toxicity

In preclinical in vivo work

INVESTMENT THESIS

Four Pillars of Differentiated Value

KOP Therapeutics is developing a differentiated precision-oncology platform designed to deliver gene-silencing therapeutics directly to cancer cells. By combining targeted delivery, modular payload flexibility, a favourable early safety profile, and a scalable development strategy, KOP aims to unlock the therapeutic potential of RNA-based medicines across multiple cancer indications.

S

Science

KOP's proprietary platform combines a tumour-targeting peptide with therapeutic oligonucleotides designed to silence cancer-driving genes directly within tumour cells. The platform has demonstrated strong gene knockdown and anti-tumour activity across multiple cancer cell lines, supporting its potential to address validated oncology targets with precision.

S

Safety

KOP's tumour-directed approach is designed to concentrate therapeutic activity within cancer cells while minimizing exposure to healthy tissue. Early preclinical studies have demonstrated anti-tumour activity without observed systemic toxicity, supporting the potential for an improved therapeutic window compared with less-targeted treatment approaches.

S

Scalability

KOP is building a modular, plug-and-play delivery platform capable of supporting multiple nucleic-acid payloads, including antisense oligonucleotides, siRNA, mRNA therapeutics and potentially gene-editing technologies. This flexibility creates opportunities to generate multiple therapeutic candidates, expand across cancer indications and establish strategic partnerships around a common delivery engine.

V

Validation

KOP's technology is supported by a growing body of scientific and preclinical evidence, including tumour-targeting confirmation, gene knockdown, cancer-cell killing and in-vivo anti-tumour activity. Ongoing third-party studies, human-tissue testing and collaborations with recognized research and development partners are designed to further validate the platform and advance lead candidates toward clinical development.

DEVELOPMENT ROADMAP

Path to IND-Enabling Studies

✓

Completed

In Vitro Validation

Up to 95% knockdown · 95 constructs screened · 4 cancer types

✓

Completed

In Vivo PoC (Charles River)

Statistically significant TGI · p=0.049 · PC3 xenograft · no observed toxicity

3

Next Milestone

96-hr Kill Study

ED50 / ED90 · Galenvs Sciences CRO · Montreal, QC

4

Target

IND-Enabling Studies

GLP tox · CMC · FDA pre-IND meeting

USE OF FUNDS

Capital Deployment Plan

96-hr Kill Study (ED50/ED90)

30%

Galenvs Sciences CRO — next immediate milestone

Lead Optimization

25%

Next-gen sequence advancement and construct refinement

IND-Enabling Studies

30%

GLP toxicology, CMC, regulatory preparation

Operations & IP

15%

Patent prosecution, team, and corporate development

INVESTOR INQUIRIES

Connect With Our Corporate Development Team

We welcome discussions with institutional investors, family offices, strategic pharma/biotech partners, and accredited investors. Our corporate development team responds within one business day.

Tibor Gajdics

President & CEO

REQUEST INVESTOR SNAPSHOT REQUEST PARTNERING DECK
KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900